Integra LifeSciences (NSDQ:IART) said it obtained 510(k) clearance from the FDA for its Integra titanium bone wedges.
The wedges are designed for corrective procedures, such as osteotomies, in treating fractures in foot bones, according to a press release.
“We’re very pleased that we can now offer surgeons another option to complete our flatfoot correction portfolio,” extremity reconstruction president Robert Paltridge said in prepared remarks. “Our titanium bone wedges provide more stability over allograft wedges. Additionally, our extensive line of pre-shaped bone wedge implants does not require custom shaping, which helps reduce surgical time.”
Plainsboro, N.J.-based Integra closed its purchase of Covidien’s (NYSE:COV) Confluent Surgical product line in January.